Dss Inc Stock Price, News & Analysis

Document Security Systems, Inc. (DSS) has promoted Todd D. Macko to interim Chief Financial Officer effective October 28, 2020. Macko, a Certified Public Accountant with over 25 years in corporate finance, will leverage his expertise in financial planning and mergers and acquisitions to advance DSS's strategic initiatives. Previously the Vice President of Finance at DSS, he has been integral in financial leadership and reporting. DSS focuses on brand protection, blockchain security, and other sectors, with plans for shareholders to benefit from future spin-offs of its subsidiaries.

Document Security Systems (DSS) reported a 59% revenue increase in Q3 2020, reaching $4.2 million. The company achieved net income of $5.4 million or $1.20 per share, a significant turnaround from a loss of $1.2 million in Q3 2019. Stockholders’ equity surged 496% to $73.3 million. Key developments include the acquisition of Impact BioMedical, a special dividend declaration, and a multi-year contract worth $3.2 million annually. DSS also launched the AuthentiGuard as a Service app and expanded its research initiatives.

DSS (NYSE American: DSS) announced the appointment of Frank D. Heuszel and Sassuan (Sam) Lee to the board of Sharing Services Global Corp (OTCQB: SHRG), where DSS holds a 37% ownership stake. Heuszel expressed enthusiasm about leveraging his experience to enhance shareholder value and grow the company's independent representative network. The collaboration aims to expand Sharing Services' market reach and product offerings, enhancing its competitive position within the direct selling industry.

Document Security Systems (DSS) has reaffirmed its plans for a two-part special share dividend of Impact BioMedical shares. Shareholders as of September 7, 2020, will receive two Bonus Shares for each DSS share held. The Bonus Shares will be distributed after Impact BioMedical's IPO, targeted for 2021. Although there are no guarantees regarding the IPO or share distribution due to market conditions, the company is committed to this path. Impact BioMedical, acquired by DSS in August 2020, holds antiviral technologies valued at $382 million.

Document Security Systems (DSS) announced a bioplastics research collaboration through its subsidiary Impact BioMedical. The partnership aims to develop five types of advanced microbial-resistant plastics to combat pathogens like SARS-CoV-2 and E. coli. Daryl Thompson, a noted researcher and twice Nobel nominee, is leading the project, targeting completion in Q4. This initiative leverages GRDG Sciences' expertise and addresses the growing market demand for microbial-resistant consumer products. DSS emphasizes the importance of this research in meeting an increasing consumer awareness of health safety.

Document Security Systems (DSS) announced a three-year contract for approximately $10 million with a leading photography company, enhancing its Premier Packaging subsidiary's portfolio. The contract, valued at around $3.2 million annually, highlights the client's confidence in Premier's capabilities and could lead to further business opportunities. Since management changes in July 2019, Premier has improved operations through investments in manufacturing and processes. As a market leader in secure printing and packaging, Premier services diverse industries, showcasing its adaptable customer service approach.

Document Security Systems (DSS) has announced a special dividend, granting shareholders two shares of Impact BioMedical for each share of DSS held as of September 7, 2020. A second tranche is anticipated but lacks a set record date. The recent acquisition of Impact BioMedical, valued at $382 million, enhances DSS's position in the biomedical field, focusing on R&D for antiviral and medical technologies. This strategic move aims to leverage Impact BioMedical’s assets to improve shareholder value and drive future growth.

Document Security Systems (DSS) announces an upcoming interview with COO Jason Grady on The RedChip Money Report, airing August 30 at 6 p.m. on Bloomberg International, reaching over 100 million homes in Europe. The interview will delve into DSS's diverse operations, including the recent acquisition of Impact BioMedical and growth strategies aimed at benefiting shareholders. The segment will also be available in the U.S. on multiple channels, showcasing insights into small-cap investment strategies and executive perspectives.

DSS has officially closed its acquisition of Impact BioMedical, marking a significant milestone for the company. This acquisition is expected to enhance DSS’s brand protection technology and healthcare sectors. DSS plans to take Impact BioMedical public through an IPO, along with a proposed two-part bonus share dividend for DSS shareholders, offering four Impact shares for each DSS share owned. Impact BioMedical’s technologies have been independently valued between $382 million and $933 million, suggesting potential growth in the healthcare market.